
Vesicor Therapeutics Is Going Public via SPAC — Here's the Setup
Vesicor Therapeutics is a development-stage microvesicle-based biotech going public through a merger with Black Hawk Acquisition Corp (NASDAQ: BKHA). The setup offers a small, pre-commercial oncology platform with a $70 million headline valuation, but shareholders should watch redemption risk, dilution, and whether the deal can actually deliver enough cash to fund development.
